Besins Healthcare   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Paris France (1885)
Status: No NME R&D (1885)

Organization Overview

First Clinical Trial
2003
NCT00272714
First Marketed Drug
2000
testosterone (delatestryl)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Ascend Therapeutics | ASCEND Therapeutics | Besins Healthcare | Besins Healthcare (funding: investigator-initiated and independent grant) | BESINS HLTHCARE | Besins Laboratory, Belgium | Besins Pharma GmbH | BHR Pharma, LLC | Dr. Kade/Besins Pharma GmbH, Rigistr. 2, 12277 Berlin | Laboratoires Besins International

Active Ingredients

Marketed Drugs (1)

testosterone (delatestryl) (2000)

Drugs in Phase 4 Trials (2)

estradiol (progynon depot) (3 trials)

progesterone (progestasert) (4 trials)

Drugs in Phase 3 Trials (3)

afimoxifene (4 trials)

testosterone (delatestryl) (4 trials)

vitamin d3 (1 trial)

Drugs in Phase 2 Trials (2)

stanolone (2 trials)

tamoxifen (nolvadex) (1 trial)

Drugs in Phase 1 Trials (1)

paclitaxel (taxol) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Atrophy (Phase 4)

Brain Injuries (Phase 3)

Brain Injuries, Traumatic (Phase 3)

Breast Carcinoma In Situ (Phase 2)

Breast Neoplasms (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Ductal, Breast (Phase 2)

Carcinoma in Situ (Phase 2)

Carcinoma, Intraductal, Noninfiltrating (Phase 2)

Colorectal Neoplasms (Phase 1)

Gonadal Disorders (Phase 2)

Hypogonadism (Phase 3)

Lymphoma (Phase 2)

Mastodynia (Phase 2)

Obstetric Labor, Premature (Phase 3)

Perinatal Death (Phase 3)

Premature Birth (Phase 3)

Prostatic Neoplasms (Phase 2)

Wounds and Injuries (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 18
  • # of Trial APIs: 8